Primary prevention of Pneumocystis carinii pneumonia by inhalation of pentamidine. Preliminary results from a placebo-controlled randomized trial. Swiss Group for Clinical Studies on AIDS
|Published in||Medizinische Klinik. 1990, vol. 85, no. Suppl 2, p. 268-270|
|Abstract||Patients with AIDS but without pneumocystis carinii pneumonia, patients with advanced AIDS-related complex (ARC), and asymptomatic patients with less than 200 CD4-positive lymphocytes/mm3 were randomized to one of two groups: group I: Inhalation of 300 mg of pentamidine every 28 days; group II: Inhalation of placebo (300 mg of Na isethionate) every 28 days. From May to November 28, 1989, 160 patients have entered the trial. Inhalations were well tolerated, with only a 6% use of bronchodilators and a 15% incidence of cough. Until now five patients died, none of them drug related. So far, six patients have developed pneumocystis carinii pneumonia; four of these were on pentamidine, and two on placebo. Five of the six cases occurred before the second inhalation. Recruitment will continue until 250 patients are enrolled.|
|Keywords||Administration, Inhalation — HIV Infections/ complications — Humans — Opportunistic Infections/ prevention & control — Pentamidine/ administration & dosage — Pneumonia, Pneumocystis/ prevention & control — Randomized Controlled Trials as Topic|
This document has no fulltext available yet, but you can contact its author by using the form below.
|HIRSCHEL, Bernard et al. Primary prevention of Pneumocystis carinii pneumonia by inhalation of pentamidine. Preliminary results from a placebo-controlled randomized trial. Swiss Group for Clinical Studies on AIDS. In: Medizinische Klinik, 1990, vol. 85, n° Suppl 2, p. 268-270. https://archive-ouverte.unige.ch/unige:9354|